FI3206692T3 - Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja - Google Patents

Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja Download PDF

Info

Publication number
FI3206692T3
FI3206692T3 FIEP15851238.4T FI15851238T FI3206692T3 FI 3206692 T3 FI3206692 T3 FI 3206692T3 FI 15851238 T FI15851238 T FI 15851238T FI 3206692 T3 FI3206692 T3 FI 3206692T3
Authority
FI
Finland
Prior art keywords
compound
use according
liver disease
fatty liver
alcohol
Prior art date
Application number
FIEP15851238.4T
Other languages
English (en)
Finnish (fi)
Inventor
Joseph K Belanoff
Hazel Hunt
Onno C Meijer
Den Heuvel Jose Van
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of FI3206692T3 publication Critical patent/FI3206692T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP15851238.4T 2014-10-15 2015-10-14 Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja FI3206692T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
FI3206692T3 true FI3206692T3 (fi) 2024-05-06

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15851238.4T FI3206692T3 (fi) 2014-10-15 2015-10-14 Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja

Country Status (22)

Country Link
US (5) US10238659B2 (2)
EP (2) EP4353310A3 (2)
JP (1) JP6761410B2 (2)
KR (1) KR102435956B1 (2)
CN (2) CN107106562B (2)
AU (1) AU2015333645B2 (2)
BR (1) BR112017007860B1 (2)
CA (1) CA2964625C (2)
DK (1) DK3206692T3 (2)
ES (1) ES2978871T3 (2)
FI (1) FI3206692T3 (2)
IL (1) IL251729B (2)
MX (1) MX2017004943A (2)
NZ (1) NZ731060A (2)
PH (1) PH12017500710B1 (2)
PL (1) PL3206692T3 (2)
PT (1) PT3206692T (2)
RU (1) RU2718921C2 (2)
SG (1) SG11201703024VA (2)
UA (1) UA123537C2 (2)
WO (1) WO2016061195A1 (2)
ZA (1) ZA201702813B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
CA3102099C (en) 2018-06-04 2023-09-26 Corcept Therapeutics Incorporated Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
CA3182272A1 (en) * 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2021226258A1 (en) * 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
MX2023007403A (es) * 2020-12-21 2023-08-16 Corcept Therapeutics Inc Método de preparación de los moduladores del receptor de ciclohexilo de pirimidina glucocorticoides.
CA3217413A1 (en) * 2021-05-05 2022-11-10 Ada Lee Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation
EP4732836A1 (en) 2024-10-22 2026-04-29 Consejo Superior De Investigaciones Científicas Ag5 compound for use in the treatment of in fatty liver diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
EP1534273A4 (en) 2002-07-18 2007-08-22 Bristol Myers Squibb Co MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
WO2006124710A1 (en) 2005-05-18 2006-11-23 Merck & Co., Inc. D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
KR20080065617A (ko) * 2005-09-19 2008-07-14 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루코코티코이드 수용체 발현의 조절
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
SI2032134T1 (sl) 2006-05-09 2015-10-30 Genzyme Corporation Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008127591A2 (en) 2007-04-13 2008-10-23 Schering Corporation Pyrimidinedione derivatives and use thereof
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
DK2685827T3 (en) * 2011-03-18 2016-05-17 Corcept Therapeutics Inc PYRIMIDIN -cyclohexyl- glucocorticoid receptor MODULATORS
SG11201703024VA (en) 2014-10-15 2017-05-30 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
JP6761410B2 (ja) 2020-09-23
AU2015333645B2 (en) 2020-01-30
CA2964625C (en) 2023-03-07
AU2015333645A1 (en) 2017-05-04
PL3206692T3 (pl) 2024-07-22
US20210085682A1 (en) 2021-03-25
CN111557942B (zh) 2023-10-03
CN111557942A (zh) 2020-08-21
KR20170066646A (ko) 2017-06-14
KR102435956B1 (ko) 2022-08-23
RU2718921C2 (ru) 2020-04-15
US10238659B2 (en) 2019-03-26
RU2017114596A (ru) 2018-11-15
US20230218621A1 (en) 2023-07-13
JP2017531013A (ja) 2017-10-19
PT3206692T (pt) 2024-04-30
IL251729B (en) 2020-03-31
IL251729A0 (en) 2017-06-29
BR112017007860A2 (pt) 2018-01-16
PH12017500710A1 (en) 2017-10-09
BR112017007860B1 (pt) 2023-03-07
EP3206692A4 (en) 2018-05-30
SG11201703024VA (en) 2017-05-30
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
UA123537C2 (uk) 2021-04-21
ES2978871T3 (es) 2024-09-23
CN107106562B (zh) 2020-08-18
EP4353310A3 (en) 2024-06-19
CA2964625A1 (en) 2016-04-21
US11590135B2 (en) 2023-02-28
DK3206692T3 (da) 2024-04-29
US12226417B2 (en) 2025-02-18
US20190151318A1 (en) 2019-05-23
MX2017004943A (es) 2017-07-19
EP3206692B1 (en) 2024-04-03
US20160106749A1 (en) 2016-04-21
ZA201702813B (en) 2019-05-29
WO2016061195A1 (en) 2016-04-21
EP4353310A2 (en) 2024-04-17
PH12017500710B1 (en) 2024-01-17
CN107106562A (zh) 2017-08-29
EP3206692A1 (en) 2017-08-23
RU2017114596A3 (2) 2019-05-08
NZ731060A (en) 2023-07-28

Similar Documents

Publication Publication Date Title
FI3206692T3 (fi) Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ME02382B (me) 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112015012693A2 (pt) derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
EP2696679A4 (en) 2'-CYAN SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
PH12016500885A1 (en) Novel heterocyclic compounds
PH12015501836A1 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
MX380619B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
AR067328A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
FR2977486B1 (fr) Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
BR122019016794B8 (pt) derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune
BR112015029504A2 (pt) inibidores quinase
WO2014052780A3 (en) Compositions and methods of use of an inappetance-controlling compound
EA201390488A1 (ru) Новые агонисты gpr 119
BR112015013414A2 (pt) derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions